RLAY · NASDAQ · STOCK
Relay Therapeutics, Inc.
$20.00
52W $3.24 – $20.79
65/100
$4.38B
-12.7
1.70
Is RLAY Bullish or Bearish?
Bullish.
Innellis AI committee rates Relay Therapeutics, Inc. (RLAY) Buy with a composite score of 65/100
, based on 6 analysts with 67% agreement.
Last updated August 11, 2026.
What Would Change This View
- Upgrade to Strong Buy
- Requires a committee score of 75.0 — +9.82 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Watch
- Requires the score to fall below 55.0 — -10.18 from today. The band boundary is 60.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
The primary driver is low leverage (debt-to-equity 0.00) -- balance sheet can absorb a shock. The main limiting factor is roe of only -42.3% -- cheap may mean cheap for a reason. The committee is constructive but not yet at full conviction.
Bull & Bear Case
Bull Case
- Price structure making higher highs and higher lows — Technical
- Trend and market structure agree -- coherent bullish picture — Technical
- Weekly trend (uptrend) confirms the daily trend -- multi-timeframe agreement — Technical
- Low leverage (debt-to-equity 0.00) -- balance sheet can absorb a shock — Risk
- VIX regime is low -- calm backdrop supports risk-taking — Macro
- Market regime is bullish (Bull market -- normal position sizing) — Macro
Bear Case
- ROE of only -42.3% -- cheap may mean cheap for a reason — Value
- MACD histogram negative -- bearish momentum — Technical
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of August 11, 2026
Overall Committee Score
65/100
Agreement
67%
Analysts
6
Conviction
Moderate
Sector Rank
Top 18%
of 192 Healthcare peers
Value Analyst
neutral
52
/ 100 · Moderate confidence
Fair value -- neither a bargain nor obviously overpriced
− ROE of only -42.3% -- cheap may mean cheap for a reason
Growth Analyst
bullish
65
/ 100 · Low confidence
Strong, accelerating growth with consistent execution
Technical Analyst
bullish
61
/ 100 · High confidence
Price action is constructive -- trend and momentum agree
+ Price structure making higher highs and higher lows
− MACD histogram negative -- bearish momentum
Risk Analyst
bullish
80
/ 100 · Low confidence
Risk profile is manageable -- leverage, volatility, and event exposure all look contained
+ Low leverage (debt-to-equity 0.00) -- balance sheet can absorb a shock
Macro Analyst
bullish
78
/ 100 · Moderate confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
+ VIX regime is low -- calm backdrop supports risk-taking
News Analyst
neutral
56
/ 100 · Low confidence
News flow is mixed or quiet -- no strong signal either way right now
Portfolio Manager
neutral
55
/ 100 · Moderate confidence
Portfolio-level factors are mixed -- worth a deliberate sizing decision, not a default-size position
+ Portfolio position concentration is currently healthy
− 2 existing position pair(s) are highly correlated already
Technical Analysis
RSI (14)
66.0
Neutral
MACD Histogram
-0.003
Bearish Momentum
Trend Direction
Uptrend
Weekly: Uptrend
Market Structure
Hh Hl
Support
$11.62
Resistance
$20.79
Bollinger %B
0.84
Inside Bands
Price vs Moving Averages
EMA 9
$19.58
Above
EMA 21
$19.18
Above
EMA 50
$17.87
Above
EMA 200
$12.77
Above
Fundamental Analysis
Valuation
84
Profitability
0
Financial Health
100
Cash Flow
15
Valuation
P/E Ratio
-12.7×
P/B Ratio
4.56×
PEG Ratio
-0.58
Dividend Yield
0.00%
52W High
$20.79
52W Low
$3.24
Quality & Growth
ROE
-4875.7%
ROA
-4449.8%
Gross Margin
—
Operating Margin
—
Revenue Growth YoY
—
Debt / Equity
0.03
AI Fundamental Assessment
[reduced confidence: limited earnings history] P/E ratio of -12.7 (inexpensive relative to a 15-40x range); Price-to-book of 4.6x; PEG ratio of -0.6 (under 1.0 suggests growth is undervalued relative to price); Return on equity of -48.8%; Return on assets of -44.5%; Net margin of -2763.6%; Gross margin of -566.6%; Current ratio of 18.27 (healthy short-term liquidity); Debt-to-equity of 0.03; Free cash flow per share is negative (-1.05); Earnings-history trend unavailable; growth based on TTM year-over-year only.
Get the Full RLAY Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →